

Priority Eligibility Criteria for COVID-19 Outpatient Therapy

(December 31, 2021)

Tier	Eligibility Criteria	Paxlovid	Molnupiravir	Sotrovimab ⁴
	<i>Treatment must be started within:</i>	5 days	5 days	10 days
	<i>Availability:</i>	<ul style="list-style-type: none"> • Region 2N, 2S, 3 • Select Meijer • Selected FQHCs • Selected THC 	<ul style="list-style-type: none"> • Limited Statewide • Select Meijer • Other sites 	<ul style="list-style-type: none"> • Statewide • Variable sites
1A	<ul style="list-style-type: none"> • Any age (per applicable EUA) with moderate to severe immunocompromise regardless of vaccine status or • Age ≥ 75 YO and not maximally vaccinated¹ 	Yes	Alternative ²	Yes
1B	<ul style="list-style-type: none"> • Age 65-74 YO, not maximally vaccinated¹, and with MI priority risk factor³ 	Not currently eligible	Alternative ²	Yes
2	<ul style="list-style-type: none"> • Age 65-74 YO and not maximally vaccinated¹ • Age < 65 YO, not maximally vaccinated¹ with MI priority risk factors³ 	Not currently eligible	Not currently eligible	Yes ⁵
3A	<ul style="list-style-type: none"> • Age ≥ 75 YO and maximally vaccinated • Age 65-74 YO, maximally vaccinated, and with MI priority risk factors³ 	Not currently eligible	Not currently eligible	Yes ⁵
3B	<ul style="list-style-type: none"> • Age 65-74 YO, maximally vaccinated, and with CDC risk factors 	Not currently eligible	Not currently eligible	Not currently eligible
4	<ul style="list-style-type: none"> • Age ≥ 65 YO and maximally vaccinated • Age < 65 YO, maximally vaccinated, and with CDC risk factors 	Not currently eligible	Not currently eligible	Not currently eligible

mAb=monoclonal antibody, FQHC=Federally Qualified Health Centers, THC=Tribal Health Centers

¹Maximally vaccinated includes completion of all recommended vaccinations for age group, including booster

²Alternatives include any other FDA authorized treatment including mAb therapy or Paxlovid that is available in a timely manner

³MI priority risk factors include:

- Obesity (BMI ≥ 35)
- Chronic respiratory disease (e.g., COPD, moderate or severe asthma requires daily inhaled corticosteroid, bronchiectasis, CF, ILD)
- Pregnancy (mAb therapy only) (Note: In pregnancy, molnupiravir should not be used and Paxlovid used with caution when other mAb is unavailable)
- Chronic Kidney Disease (stage III, IV, or end stage CKD-GFR) (special considerations with Paxlovid)
- Cardiovascular disease (e.g., HTN, valvular disease, CVA, PAD, CHF)
- Diabetes

⁴Sotrovimab is currently the only mAb therapy with activity against the Omicron variant and is in limited supply. Other mAb medications may be considered for non-Omicron.

⁵Use in lower tiers should be done only when higher tiers are able to be treated in a timely manner. Higher tier patients are a priority.